Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for DIPG, DMG, or B7-H3-Positive Recurrent or Refractory Pediatric Central Nervous System Tumors
What is the goal of the study?
In this phase 1 clinical trial, Seattle Children's is testing CAR T-cell therapy in children and young adults with recurrent or refractory central nervous system (CNS) tumors, including diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). Researchers are working to answer these questions: -Is this T-cell therapy safe to give to children and young adults with recurrent or refractory CNS tumors, including DIPG and DMG? -What is the best dose of this therapy?
Who can participate in the study?
This study might be a good fit for children and young adults who: - Are ages 1 to 26 years old - Have recurrent or refractory CNS tumors, including DIPG and DMG Researchers use many other factors to decide whether or not a patient can take part in a study (called includion or exclusion criteria). The study team at Seattle Children's can explain what these factors mean for you or your child.